Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Scleroderma Relat Disord ; 8(2): 87-100, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37287946

ABSTRACT

Autologous haematopoietic stem cell transplantation is now well-established as an effective treatment for severe systemic sclerosis with clear demonstration of favourable end-organ and survival outcomes. Treatment-related cardiotoxicity remains the predominant safety concern and contraindicates autologous haematopoietic stem cell transplantation in patients with severe cardiopulmonary disease. In this review, we describe the cardiovascular outcomes of autologous haematopoietic stem cell transplantation recipients, discuss the potential mechanisms of cardiotoxicity and propose future mitigating strategies.

2.
Intern Med J ; 52(10): 1826-1830, 2022 10.
Article in English | MEDLINE | ID: mdl-36266066

ABSTRACT

Cardiac light chain (AL) amyloidosis is a condition with a very poor prognosis. We report a retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and dexamethasone in late-stage cardiac AL amyloidosis. The primary end points were overall survival and haematological response. Both regimens provided meaningful responses in this difficult to treat patient group.


Subject(s)
Amyloidosis , Immunoglobulin Light-chain Amyloidosis , Humans , Bortezomib , Immunoglobulin Light-chain Amyloidosis/drug therapy , Melphalan , Retrospective Studies , Dexamethasone , Amyloidosis/drug therapy , Cyclophosphamide
3.
J Heart Lung Transplant ; 41(6): 829-839, 2022 06.
Article in English | MEDLINE | ID: mdl-35418322

ABSTRACT

BACKGROUND: Frailty is associated with adverse outcomes in advanced heart failure. We studied the impact of frailty on postoperative outcomes in bridge to transplant (BTT) durable mechanical circulatory support (MCS) recipients. METHODS: Patients undergoing left ventricular assist device (LVAD, n = 96) or biventricular support (BiV, n = 11) as BTT underwent frailty assessment. Frailty was defined as ≥ 3 physical domains of the Fried's Frailty Phenotype (FFP) or ≥ 2 physical domains of the FFP plus cognitive impairment on the Montreal Cognitive Assessment (MoCA). RESULTS: No difference in mortality at 360 days was observed in frail (n = 6/38, 15.8%) vs non-frail (n = 4/58, 6.9%) LVAD supported patients, p = 0.19. However, there was a significant excess mortality in frail BiV (n = 4/5) vs non-frail BiV (n = 0/6) supported patients, p = 0.013. In all patients, frail patients compared to non-frail patients experienced longer intensive care unit stay, 12 vs 6 days (p < 0.0001) and hospital length of stay, 48 vs 27 days (p < 0.0001). There was no difference in hemocompatibility and infection related adverse events. The majority (n = 22/29, 75.9%) of frail patients became non-frail following MCS; contrastingly, a minority (n = 3/42, 7.1%) became frail from being non-frail (p = 0.0003). CONCLUSIONS: Abnormal markers of frailty are common in patients undergoing BTT-MCS support and those used herein predict mortality in BiV-supported patients, but not in LVAD patients. These findings may help us better identify patients who will benefit most from BiV-BTT therapy.


Subject(s)
Frailty , Heart Failure , Heart Transplantation , Heart-Assist Devices , Frailty/complications , Heart Failure/etiology , Heart Failure/surgery , Heart-Assist Devices/adverse effects , Humans , Morbidity , Transplant Recipients
4.
Clin Infect Dis ; 75(7): 1235-1238, 2022 09 30.
Article in English | MEDLINE | ID: mdl-35275984

ABSTRACT

We present the first published case of successfully treated disseminated Aspergillus lentulus infection in a solid organ transplant recipient with invasive pulmonary disease, endophthalmitis, and a cerebral abscess. This case highlights important challenges associated with treating A. lentulus, particularly regarding antifungal resistance and toxicities associated with long-term antifungal therapy.


Subject(s)
Antifungal Agents , Heart Transplantation , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Aspergillus , Drug Resistance, Fungal , Heart Transplantation/adverse effects , Humans
5.
Transplantation ; 106(1): 200-209, 2022 01 01.
Article in English | MEDLINE | ID: mdl-33988342

ABSTRACT

BACKGROUND: The aim of this study was to validate our previous finding that frailty predicts early mortality in patients with advanced heart failure (AHF) and that including cognition in the frailty assessment enhances the prediction of mortality. METHODS: Patients with AHF referred to our Transplant Unit between November 2015 and April 2020 underwent physical frailty assessment using the modified Fried physical frailty (PF) phenotype as well as cognitive assessment using the Montreal Cognitive Assessment to identify patients who were cognitively frail (CogF). We assessed the predictive value of the 2 frailty measures (PF ≥ 3 of 5 = frail; CogF ≥ 3 of 6 = frail) for pretransplant mortality. RESULTS: Three hundred thirteen patients (233 male and 80 female; age 53 ± 13 y) were assessed. Of these, 224 patients (72%) were nonfrail and 89 (28%) were frail using the PF. The CogF assessment identified an additional 30 patients as frail: 119 (38%). Frail patients had significantly increased mortality as compared to nonfrail patients. Ventricular assist device and heart transplant-censored survival at 12 mo was 92 ± 2 % for nonfrail and 69 ± 5% for frail patients (P < 0.0001) using the CogF instrument. CONCLUSIONS: This study validates our previously published findings that frailty is prevalent in patients with AHF referred for heart transplantation. PF predicts early mortality. The addition of cognitive assessment to the physical assessment of frailty identifies an additional cohort of patients with a similarly poor prognosis.


Subject(s)
Cognitive Dysfunction , Frailty , Heart Failure , Heart Transplantation , Heart-Assist Devices , Aged , Cognitive Dysfunction/complications , Cognitive Dysfunction/diagnosis , Female , Frail Elderly , Frailty/complications , Frailty/diagnosis , Geriatric Assessment , Heart Failure/complications , Heart Failure/diagnosis , Heart Failure/surgery , Humans , Male
6.
J Heart Lung Transplant ; 40(2): 87-94, 2021 02.
Article in English | MEDLINE | ID: mdl-33279391

ABSTRACT

BACKGROUND: Frailty is prevalent in the patients with advanced heart failure; however, its impact on clinical outcomes after heart transplantation (HTx) is unclear. The aim of this study was to assess the impact of pre-transplant frailty on mortality and the duration of hospitalization after HTx. METHODS: We retrospectively reviewed the post-transplant outcomes of 140 patients with advanced heart failure who had undergone frailty assessment within the 6-month interval before HTx: 43 of them were frail (F) and 97 were non-frail (NF). RESULTS: Post-transplant survival rates for the NF cohort at 1 and 12 months were 97% (93-100) and 95% (91-99) (95% CI), respectively. In contrast, post-transplant survival rates for the F cohort at the same time points were 86% (76-96) and 74% (60-84) (p < 0.0008 vs NF cohort), respectively. The Cox proportional hazards regression analysis demonstrated that pre-transplant frailty was an independent predictor of post-transplant mortality with a hazard ratio of 3.8 (95% CI: 1.4-10.5). Intensive care unit and hospital length of stay were 2 and 7 days longer in the F cohort (both p < 0.05), respectively, than in the NF cohort. CONCLUSIONS: Frailty within 6 months before HTx is independently associated with increased mortality and prolonged hospitalization after transplantation. Future research should focus on the development of strategies to mitigate the adverse effects of pre-transplant frailty.


Subject(s)
Frailty/epidemiology , Heart Failure/surgery , Heart Transplantation/mortality , Intensive Care Units/statistics & numerical data , Risk Assessment/methods , Female , Follow-Up Studies , Frailty/etiology , Heart Failure/complications , Heart Failure/mortality , Humans , Male , Middle Aged , New South Wales/epidemiology , Prognosis , Retrospective Studies , Survival Rate/trends , Time Factors
7.
Heart Lung Circ ; 27(7): 792-797, 2018 Jul.
Article in English | MEDLINE | ID: mdl-28919071

ABSTRACT

BACKGROUND: There are continuing bed constraints in percutaneous coronary intervention centres (PCI) so efficient patient triage from referral hospitals is pivotal. To evaluate a strategy of PCI centre (PCIC) bed-sparing we examined return of patients to referral hospitals screened by the RETRIEVE (REverse TRIage EVEnts) criteria and validated its use as a tool for screening suitability for same day transfer of non-ST-elevation acute coronary syndrome (NSTEACS) patients post PCI to their referring non-PCI centre (NPCIC). METHODS: From May 2008 to May 2011, 433 NSTEACS patients were prospectively screened for suitability for same day transfer back to the referring hospital at the completion of PCI. Of these patients, 212 were excluded from same day transfer using the RETRIEVE criteria and 221 patients met the RETRIEVE criteria and were transferred back to their NPCIC. RESULTS: Over the study period, 218 patients (98.6%) had no major adverse events. The primary endpoint (death, arrhythmia, myocardial infarction, major bleeding event, cerebrovascular accident, major vascular site complication, or requirement for return to the PCIC) was seen in only three transferred patients (1.4%). CONCLUSIONS: The RETRIEVE criteria can be used successfully to identify NSTEACS patients suitable for transfer back to NPCIC following PCI. Same day transfer to a NPCIC using the RETRIEVE criteria was associated with very low rates of major complications or repeat transfer and appears to be as safe as routine overnight observation in a PCIC.


Subject(s)
Acute Coronary Syndrome/surgery , Electrocardiography , Patient Readmission/trends , Patient Transfer , Percutaneous Coronary Intervention/methods , Postoperative Complications/epidemiology , Triage/organization & administration , Coronary Angiography , Female , Follow-Up Studies , Humans , Incidence , Male , Middle Aged , New South Wales/epidemiology , Prospective Studies , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL